Sandbox Reserved 1107: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 5: Line 5:


== MraY ==
== MraY ==
[http://proteopedia.org/wiki/index.php/4j72 MraY], called also '''phospho-N-acetylmuramoyl-pentapeptide-transferase'''  or '''UDP-MurNAc-pentapeptide phosphotransferase''', with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.8.13 2.7.8.13], is an integral membrane enzyme involved in peptidoglycan biosynthesis <ref name="one">PMID:29778697</ref> <ref name="two">PMID:27511599</ref>.MraY is encoded by the [https://www.ncbi.nlm.nih.gov/gene/1192662 mraY gene] and  belongs to a subfamily of the polyprenyl-phosphate N-acetyl hexosamine 1-phosphate transferase (PNPT) superfamily <ref name="three">PMID:23990562</ref>. MRAY is a promising candidate for the development of new antibiotics. In fact, it is the target of five classes of natural nucleoside inhibitors with potent antibacterial activity: the liposidomycins/caprazamycins, capuramycins, mureidomycins, muraymycins, and tunicamycins <ref name="two"/> <ref name="four">PMID:29438582</ref>.The structure presented in this page correspond to the MraY protein from the thermophile [https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=224324 ''Aquifex aeolicus'' strain VF5], expressed in ''Escherichia coli'', in complex with carbacaprazamycin.  
[http://proteopedia.org/wiki/index.php/4j72 MraY], called also '''phospho-N-acetylmuramoyl-pentapeptide-transferase'''  or '''UDP-MurNAc-pentapeptide phosphotransferase''', with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.8.13 2.7.8.13], is an integral membrane enzyme involved in peptidoglycan biosynthesis <ref name="one">PMID:29778697</ref> <ref name="two">PMID:27511599</ref>.MraY is encoded by the [https://www.ncbi.nlm.nih.gov/gene/1192662 mraY gene] and  belongs to a subfamily of the polyprenyl-phosphate N-acetyl hexosamine 1-phosphate transferase (PNPT) superfamily <ref name="three">PMID:23990562</ref>. MRAY is a promising candidate for the development of new antibiotics. In fact, it is the target of five classes of natural nucleoside inhibitors with potent antibacterial activity: the liposidomycins/caprazamycins, capuramycins, mureidomycins, muraymycins, and tunicamycins <ref name="two"/> <ref name="four">PMID:29438582</ref>.The structure presented in this page correspond to the MraY protein from the thermophile [https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=224324 ''Aquifex aeolicus'' strain VF5] (MraYAA) in complex with carbacaprazamycin.MraYAA was expressed in ''Escherichia coli''.


== Carbacaprazamycin  ==
== Carbacaprazamycin  ==


<scene name='42/421575/Carbacaprazamycin/1'>Carbacaprazamycin</scene> is a chemically stable analog of caprazamycin nucleoside inhibitors <ref name="more1">DOI:10.1021/id5000376</ref>.  
<scene name='42/421575/Carbacaprazamycin/1'>Carbacaprazamycin</scene> is a chemically stable analog of caprazamycin nucleoside inhibitors <ref name="more1">DOI:10.1021/id5000376</ref>. One particular characteristic of caprazamycin nucleoside inhibitors is that they have uridine on their structure. It has been shown that Mray inhibitors contains a uridine moiety.
 
 
== Relevance  ==


Drug resistant bacteria are the cause of death of millions of people worldwide. In the USA alone, hospital infections associated with antibiotic-resistant pathogens cause 99 000 deaths per year<ref name="more2">PMID:30349322</ref>. The development of new antibiotics with new mechanism of action is urgent. Structural analysis of the binding of carbacaprazamycin to MraY provides a better understanding of the chemical logic of MraY inhibition, which can help in the development of novel approaches for the design of antibiotics targeting MraY.
Drug resistant bacteria are the cause of death of millions of people worldwide. In the USA alone, hospital infections associated with antibiotic-resistant pathogens cause 99 000 deaths per year<ref name="more2">PMID:30349322</ref>. The development of new antibiotics with new mechanism of action is urgent. Structural analysis of the binding of carbacaprazamycin to MraY provides a better understanding of the chemical logic of MraY inhibition, which can help in the development of novel approaches for the design of antibiotics targeting MraY.

Revision as of 01:33, 17 January 2020

Crystal structure of two MraY dimers

Drag the structure with the mouse to rotate

References